Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18936853 | 1.00 | CNR1 (0.61) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL18936851 | 0.96 | CNR1 (0.66) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL2190833 | 0.96 | CNR1 (0.66) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL18936854 | 0.92 | CNR1 (0.59) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL2191225 | 0.92 | CNR1 (0.59) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL2190944 | 0.88 | CNR1 (0.69) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL2188464 | 0.88 | CNR1 (0.64) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL2188466 | 0.88 | CNR1 (0.64) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL12417778 | 0.88 | CNR1 (0.64) | CNR1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL2193488 | 0.88 | CNR1 (0.59) | CNR1EPHX2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521447-B1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | claimed |
| US-8969354-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | claimed |
| EP-2521447-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | claimed |
| WO-2011085211-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | claimed |
| US-20180271820-A1 | METHODS OF TREATING HEART FAILURE | RAJASEKHAR VIJAYKUMAR (US) | 2018-09-27 | — | — | US | disclosed |
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | RAJASEKHAR VIJAYKUMAR (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2521447-B1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9289503-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8969354-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2521447-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011085211-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | FH, FABP3, HMGCR | CNR1 4358/4885EPHX2 611/4885MAPT 3076/4885 |
| US-20180271820-A1 | METHODS OF TREATING HEART FAILURE | FABP3, FH, TNNI3 | CNR1 3874/4885EPHX2 728/4885MAPT 4229/4885 |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885EPHX2 1767/4885MAPT 253/4885 |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885EPHX2 1767/4885MAPT 253/4885 |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885EPHX2 1767/4885MAPT 253/4885 |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885EPHX2 1767/4885MAPT 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.